Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

P&G Restructuring Program Early Termination Slated For Mid-2003

This article was originally published in The Tan Sheet

Executive Summary

Procter & Gamble expects to record after-tax savings of $1.4 bil.-$1.5 bil. by the end of its current fiscal year on June 30, when it plans to brings its restructuring efforts to a close

You may also be interested in...



P&G Expects To Save $900 Mil. By FY 2004 In $1.9 Bil. Restructuring Effort

Procter & Gamble expects to record annual after-tax cost savings of $900 mil. by fiscal 2004 under the latest phase of the company's Organization 2005 restructuring program, CEO Durk Jager announced June 9. Savings over the next fiscal year are not expected to be significant, but P&G said it will "ramp up" the program through FY 2004.

P&G's Byrnes To Head Health Care & Corporate New Ventures Unit

Procter & Gamble exec Bruce Byrnes will head up the company's new Health Care & Corporate New Ventures Unit under a restructuring program announced Sept. 9.

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS094915

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel